+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Smart Inhalers Market by Product, Indication, and Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2021-2030

  • PDF Icon

    Report

  • 173 Pages
  • February 2022
  • Region: Global
  • Allied Market Research
  • ID: 5578235
UP TO OFF until Nov 15th 2024
The global smart inhalers market was valued at $118 million in 2020, and is estimated to reach $1,113.57 million by 2030, growing at a CAGR of 25.1% from 2021 to 2030.



Smart inhalers are devices used for delivering a variety of medication through inhalation and can be connected to devices such as smartphones or any digital device. The drugs used in the inhalers include, anti-cholinergic, glucocorticoids, insulin, and beta-agonists for the treatment and prevention of respiratory diseases, such as asthma and chronic obstructive pulmonary diseases (COPD). Smart inhalers have sensors that send feeds back, reminders and monitors an individual’s health regularly. It also notifies about high pollution areas as well high pollen threat.

Smart inhalers have proved to increase the adherence rate in patients suffering from asthma and COPD. Moreover, smart inhalers also help to monitor the technique used for inhaling the medicine in an effective manner as compared to normal inhalers. Smart Inhalers are of two types, namely metered dose inhalers and dry powder inhalers.

This market is majorly driven by increase in population suffering from asthma and COPD. Increase in air pollution directly increases asthma and other respiratory cases, which in turn, boosts the demand for smart monitoring devices. According to the World Health Organization (WHO), chronic obstructive pulmonary disease (COPD) is the third leading cause of death globally, causing 3.23 million deaths in 2019 and more than 80% of these deaths occurred in low and middle income countries. Thus, such large mortality and unmet medical demands can be reduced by increased initiatives and utilization of smart inhalers and is an opportunity for the investors to invest in such countries.

For instance, in July 2020, Novartis International AG, one of the leading players received European Commission’s (EC) approval for Enerzair Breezhaler, the first digital companion (sensor and app) that can be prescribed alongside a treatment for uncontrolled asthma in the European Union. It was developed in collaboration with Propeller Health’s app and sensor custom-built for the Breezhaler device. Thus, launch of such products and collaborations among the key market players further boost the market growth.

Market players have invested in various developing smart inhalers products that aid in monitoring asthma and COPD, wherein, the data acquired by the sensors of these smart inhalers is shared with the patient and healthcare professionals to track their inhaler usage. The data monitored is then shared using the Bluetooth technology to their mobile apps through an online platform and subsequently, electronic health records (EHR) or electronic medical records (EMR) are maintained.

Smart inhalers are expected to increase the adherence rate of patients to traditional inhalers. Unintended non-adherence arises when patients misunderstand instructions and forget or have physical problems such as poor coordination or eyesight, thus leading to limited ability to take their medicines. Smart inhalers, such as the Adherium’s Hailie solution is a cloud-based platform, which captures medication use data from Bluetooth enabled sensors that wraps around patient inhalers and provides real-time feedback to patients via the Hailie app and to their physicians via the Hailie portal. Increase in non-adherence is known to be a source of disease to patients as well as financial burden to payers and prescribers. Thus, increase in adherence to smart inhalers is expected to improve the treatment of asthma and COPD patients.

However, as smart inhalers are wirelessly connected and keep a record of the patient’s data, the risk of data leakage and misuse of data increases significantly. As smart inhaler is a new device, its acceptance among patients as well as physicians is considerably low and is thus, expected to restrain the growth of the market. Furthermore, presence of a plethora of products in the pipeline and high market potential in untapped emerging economies are anticipated to serve as attractive opportunities for market growth during the forecast period.

The smart inhalers market is segmented into product, indication, distribution channel, and region. On the basis of product, the market is segmented into inhalers and nebulizers. The inhalers are further bifurcated dry powdered inhalers (DPIs) and metered dose inhalers (MDI's) . On the basis of indication, the market is segmented into asthma and COPD. On the basis of distribution channel, the market is bifurcated in to hospital pharmacies and retail pharmacies.

Region wise, it is analyzed across North America, Europe, Asia-Pacific, and Latin America, Middle East, and Africa (LAMEA).

The major players profiled in the report are Adherium Limited, Aptar Group Inc. (Cohero Health Inc.), AstraZeneca, Inc., Cognita Labs, Llc., GlaxoSmithKline Plc, Novartis AG, OPKO Health Inc., Philip Morris International Inc. (Vectura Group Plc), ResMed Inc. (Propeller Health) and Teva Pharmaceutical Industries Ltd.

KEY BENEFITS FOR STAKEHOLDERS

  • This report provides an extensive analysis of the current and emerging market trends and dynamics in the global smart inhalers market to identify the prevailing opportunities
  • This study presents the competitive landscape of the global market to predict the competitive environment across geographies
  • Comprehensive analysis of factors that drive and restrict the market growth is provided
  • Region- & country-wise analysis is provided to understand the market trends and dynamics

KEY MARKET SEGMENTS


By Product

  • Inhalers
  • Dry Powdered Inhalers (DPIs)
  • Metered Dose Inhalers (MDI's)
  • Nebulizers

By Indication

  • Asthma
  • COPD

By Distribution Channel

  • Hospitals Pharmacies
  • Retail Pharmacies

By Region

  • North America
  • US
  • Canada
  • Mexico
  • Europe
  • UK
  • Germany
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • UAE
  • Turkey
  • Saudi Arabia
  • Rest of LAMEA

KEY MARKET PLAYERS

  • Adherium Limited
  • Aptar Group Inc (Cohero Health Inc)
  • AstraZeneca, Inc
  • Cognita Labs, LLC
  • GlaxoSmithKline Plc
  • Novartis AG
  • OPKO Health Inc
  • Philip Morris International Inc (Vectura Group Plc)
  • Resmed Inc (Propeller Health)
  • Teva Pharmaceutical Industries Ltd

 

Please note:

  • Online Access price format is valid for 60 days access. Printing is not enabled.
  • PDF Single and Enterprise price formats enable printing.

 

Table of Contents

Chapter 1: Introduction
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models
Chapter 2: Executive Summary
2.1. Cxo Perspective
Chapter 3: Market Landscape
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
3.3.1. Bargaining Power of Suppliers
3.3.2. Threat of New Entrants
3.3.3. Threat of Substitutes
3.3.4. Competitive Rivalry
3.3.5. Bargaining Power Among Buyers
3.4. Market Share Analysis/Top Player Positioning
3.4.1. Market Share Analysis/Top Player Positioning 2020
3.5. Market Dynamics
3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities
3.6. Covid-19 Impact Analysis
Chapter 4: Smart Inhalers Market, by Product
4.1. Market Overview
4.1.1Market Size and Forecast, by Product
4.2. Inhalers
4.2.1. Key Market Trends, Growth Factors and Opportunities
4.2.2. Market Size and Forecast, by Region
4.2.3. Market Share Analysis, by Country
4.2.4. Dry Powdered Inhalers (Dpis)
4.2.4.1. Market Size and Forecast
4.2.5. Metered Dose Inhalers (Mdis)
4.2.5.1. Market Size and Forecast
4.3. Nebulizers
4.3.1. Key Market Trends, Growth Factors and Opportunities
4.3.2. Market Size and Forecast, by Region
4.3.3. Market Share Analysis, by Country
Chapter 5: Smart Inhalers Market, by Indication
5.1. Market Overview
5.1.1Market Size and Forecast, by Indication
5.2. Asthma
5.2.1. Market Size and Forecast, by Region
5.2.2. Market Share Analysis, by Country
5.3. Copd
5.3.1. Market Size and Forecast, by Region
5.3.2. Market Share Analysis, by Country
Chapter 6: Smart Inhalers Market, by End-user
6.1. Market Overview
6.1.1Market Size and Forecast, by End-user
6.2. Hospital Pharmacies
6.2.1. Market Size and Forecast, by Region
6.2.2. Market Share Analysis, by Country
6.3. Retail Pharmacies
6.3.1. Market Size and Forecast, by Region
6.3.2. Market Share Analysis, by Country
Chapter 7: Smart Inhalers Market, by Region
7.1. Market Overview
7.1.1Market Size and Forecast, by Region
7.2. North America
7.2.1. Key Market Trends and Opportunities
7.2.2. Market Size and Forecast, by Product
7.2.3. Market Size and Forecast, by Indication
7.2.4. Market Size and Forecast, by End-user
7.2.5. Market Size and Forecast, by Country
7.2.6. United States Smart Inhalers Market
7.2.6.1. Market Size and Forecast, by Product
7.2.6.2. Market Size and Forecast, by Indication
7.2.6.3. Market Size and Forecast, by End-user
7.2.7. Canada Smart Inhalers Market
7.2.7.1. Market Size and Forecast, by Product
7.2.7.2. Market Size and Forecast, by Indication
7.2.7.3. Market Size and Forecast, by End-user
7.2.8. Mexico Smart Inhalers Market
7.2.8.1. Market Size and Forecast, by Product
7.2.8.2. Market Size and Forecast, by Indication
7.2.8.3. Market Size and Forecast, by End-user
7.3. Europe
7.3.1. Key Market Trends and Opportunities
7.3.2. Market Size and Forecast, by Product
7.3.3. Market Size and Forecast, by Indication
7.3.4. Market Size and Forecast, by End-user
7.3.5. Market Size and Forecast, by Country
7.3.6. France Smart Inhalers Market
7.3.6.1. Market Size and Forecast, by Product
7.3.6.2. Market Size and Forecast, by Indication
7.3.6.3. Market Size and Forecast, by End-user
7.3.7. Germany Smart Inhalers Market
7.3.7.1. Market Size and Forecast, by Product
7.3.7.2. Market Size and Forecast, by Indication
7.3.7.3. Market Size and Forecast, by End-user
7.3.8. Italy Smart Inhalers Market
7.3.8.1. Market Size and Forecast, by Product
7.3.8.2. Market Size and Forecast, by Indication
7.3.8.3. Market Size and Forecast, by End-user
7.3.9. U. K Smart Inhalers Market
7.3.9.1. Market Size and Forecast, by Product
7.3.9.2. Market Size and Forecast, by Indication
7.3.9.3. Market Size and Forecast, by End-user
7.3.10. Russia Smart Inhalers Market
7.3.10.1. Market Size and Forecast, by Product
7.3.10.2. Market Size and Forecast, by Indication
7.3.10.3. Market Size and Forecast, by End-user
7.3.11. Rest of Europe Smart Inhalers Market
7.3.11.1. Market Size and Forecast, by Product
7.3.11.2. Market Size and Forecast, by Indication
7.3.11.3. Market Size and Forecast, by End-user
7.4. Asia-Pacific
7.4.1. Key Market Trends and Opportunities
7.4.2. Market Size and Forecast, by Product
7.4.3. Market Size and Forecast, by Indication
7.4.4. Market Size and Forecast, by End-user
7.4.5. Market Size and Forecast, by Country
7.4.6. China Smart Inhalers Market
7.4.6.1. Market Size and Forecast, by Product
7.4.6.2. Market Size and Forecast, by Indication
7.4.6.3. Market Size and Forecast, by End-user
7.4.7. Japan Smart Inhalers Market
7.4.7.1. Market Size and Forecast, by Product
7.4.7.2. Market Size and Forecast, by Indication
7.4.7.3. Market Size and Forecast, by End-user
7.4.8. India Smart Inhalers Market
7.4.8.1. Market Size and Forecast, by Product
7.4.8.2. Market Size and Forecast, by Indication
7.4.8.3. Market Size and Forecast, by End-user
7.4.9. Australia Smart Inhalers Market
7.4.9.1. Market Size and Forecast, by Product
7.4.9.2. Market Size and Forecast, by Indication
7.4.9.3. Market Size and Forecast, by End-user
7.4.10. Rest of Asia-Pacific Smart Inhalers Market
7.4.10.1. Market Size and Forecast, by Product
7.4.10.2. Market Size and Forecast, by Indication
7.4.10.3. Market Size and Forecast, by End-user
7.5. Lamea
7.5.1. Key Market Trends and Opportunities
7.5.2. Market Size and Forecast, by Product
7.5.3. Market Size and Forecast, by Indication
7.5.4. Market Size and Forecast, by End-user
7.5.5. Market Size and Forecast, by Country
7.5.6. Brazil Smart Inhalers Market
7.5.6.1. Market Size and Forecast, by Product
7.5.6.2. Market Size and Forecast, by Indication
7.5.6.3. Market Size and Forecast, by End-user
7.5.7. Saudi Arabia Smart Inhalers Market
7.5.7.1. Market Size and Forecast, by Product
7.5.7.2. Market Size and Forecast, by Indication
7.5.7.3. Market Size and Forecast, by End-user
7.5.8. Uae Smart Inhalers Market
7.5.8.1. Market Size and Forecast, by Product
7.5.8.2. Market Size and Forecast, by Indication
7.5.8.3. Market Size and Forecast, by End-user
7.5.9. Turkey Smart Inhalers Market
7.5.9.1. Market Size and Forecast, by Product
7.5.9.2. Market Size and Forecast, by Indication
7.5.9.3. Market Size and Forecast, by End-user
7.5.10. Rest of LAMEA Smart Inhalers Market
7.5.10.1. Market Size and Forecast, by Product
7.5.10.2. Market Size and Forecast, by Indication
7.5.10.3. Market Size and Forecast, by End-user
Chapter 8: Company Profiles
8.1. Adherium Limited
8.1.1. Company Overview
8.1.2. Key Executives
8.1.3. Company Snapshot
8.1.4. Operating Business Segments
8.1.5. Product Portfolio
8.1.6. Business Performance
8.1.7. Key Strategic Moves and Developments
8.2. Aptar Group Inc. (Cohero Health Inc.)
8.2.1. Company Overview
8.2.2. Key Executives
8.2.3. Company Snapshot
8.2.4. Operating Business Segments
8.2.5. Product Portfolio
8.2.6. Business Performance
8.2.7. Key Strategic Moves and Developments
8.3. Astrazeneca, Inc.
8.3.1. Company Overview
8.3.2. Key Executives
8.3.3. Company Snapshot
8.3.4. Operating Business Segments
8.3.5. Product Portfolio
8.3.6. Business Performance
8.3.7. Key Strategic Moves and Developments
8.4. Cognita Labs, LLC
8.4.1. Company Overview
8.4.2. Key Executives
8.4.3. Company Snapshot
8.4.4. Operating Business Segments
8.4.5. Product Portfolio
8.4.6. Key Strategic Moves and Developments
8.5. GlaxoSmithKline plc
8.5.1. Company Overview
8.5.2. Key Executives
8.5.3. Company Snapshot
8.5.4. Operating Business Segments
8.5.5. Product Portfolio
8.5.6. Business Performance
8.6. Novartis AG
8.6.1. Company Overview
8.6.2. Key Executives
8.6.3. Company Snapshot
8.6.4. Operating Business Segments
8.6.5. Product Portfolio
8.6.6. Business Performance
8.6.7. Key Strategic Moves and Developments
8.7. Opko Health Inc.
8.7.1. Company Overview
8.7.2. Key Executives
8.7.3. Company Snapshot
8.7.4. Operating Business Segments
8.7.5. Product Portfolio
8.7.6. Business Performance
8.8. Philip Morris International Inc. (Vectura Group plc)
8.8.1. Company Overview
8.8.2. Key Executives
8.8.3. Company Snapshot
8.8.4. Operating Business Segments
8.8.5. Product Portfolio
8.8.6. Business Performance
8.8.7. Key Strategic Moves and Developments
8.9. Resmed Inc. (Propeller Health)
8.9.1. Company Overview
8.9.2. Key Executives
8.9.3. Company Snapshot
8.9.4. Operating Business Segments
8.9.5. Product Portfolio
8.9.6. Business Performance
8.9.7. Key Strategic Moves and Developments
8.10. Teva Pharmaceutical Industries Ltd.
8.10.1. Company Overview
8.10.2. Key Executives
8.10.3. Company Snapshot
8.10.4. Operating Business Segments
8.10.5. Product Portfolio
8.10.6. Business Performance
8.10.7. Key Strategic Moves and Developments
List of Tables
Table 1. Global Smart Inhalers Market, by Product, 2020-2030 ($Million)
Table 2. Global Smart Inhalers Market for Inhalers, by Region, 2020-2030 ($Million)
Table 3. Global Smart Inhalers Market for Nebulizers, by Region, 2020-2030 ($Million)
Table 4. Global Smart Inhalers Market, by Indication, 2020-2030 ($Million)
Table 5. Global Smart Inhalers Market for Asthma, by Region, 2020-2030 ($Million)
Table 6. Global Smart Inhalers Market for Copd, by Region, 2020-2030 ($Million)
Table 7. Global Smart Inhalers Market, by End-user, 2020-2030 ($Million)
Table 8. Global Smart Inhalers Market for Hospital Pharmacies, by Region, 2020-2030 ($Million)
Table 9. Global Smart Inhalers Market for Retail Pharmacies, by Region, 2020-2030 ($Million)
Table 10. Global Smart Inhalers Market, by Region, 2020-2030 ($Million)
Table 11. North America Smart Inhalers, by Product, 2020-2030 ($Million)
Table 12. North America Smart Inhalers, by Indication, 2020-2030 ($Million)
Table 13. North America Smart Inhalers, by End-user, 2020-2030 ($Million)
Table 14. United States Smart Inhalers, by Product, 2020-2030 ($Million)
Table 15. United States Smart Inhalers, by Indication, 2020-2030 ($Million)
Table 16. United States Smart Inhalers, by End-user, 2020-2030 ($Million)
Table 17. Canada Smart Inhalers, by Product, 2020-2030 ($Million)
Table 18. Canada Smart Inhalers, by Indication, 2020-2030 ($Million)
Table 19. Canada Smart Inhalers, by End-user, 2020-2030 ($Million)
Table 20. Mexico Smart Inhalers, by Product, 2020-2030 ($Million)
Table 21. Mexico Smart Inhalers, by Indication, 2020-2030 ($Million)
Table 22. Mexico Smart Inhalers, by End-user, 2020-2030 ($Million)
Table 23. Europe Smart Inhalers, by Product, 2020-2030 ($Million)
Table 24. Europe Smart Inhalers, by Indication, 2020-2030 ($Million)
Table 25. Europe Smart Inhalers, by End-user, 2020-2030 ($Million)
Table 26. France Smart Inhalers, by Product, 2020-2030 ($Million)
Table 27. France Smart Inhalers, by Indication, 2020-2030 ($Million)
Table 28. France Smart Inhalers, by End-user, 2020-2030 ($Million)
Table 29. Germany Smart Inhalers, by Product, 2020-2030 ($Million)
Table 30. Germany Smart Inhalers, by Indication, 2020-2030 ($Million)
Table 31. Germany Smart Inhalers, by End-user, 2020-2030 ($Million)
Table 32. Italy Smart Inhalers, by Product, 2020-2030 ($Million)
Table 33. Italy Smart Inhalers, by Indication, 2020-2030 ($Million)
Table 34. Italy Smart Inhalers, by End-user, 2020-2030 ($Million)
Table 35. United Kingdom Smart Inhalers, by Product, 2020-2030 ($Million)
Table 36. United Kingdom Smart Inhalers, by Indication, 2020-2030 ($Million)
Table 37. United Kingdom Smart Inhalers, by End-user, 2020-2030 ($Million)
Table 38. Russia Smart Inhalers, by Product, 2020-2030 ($Million)
Table 39. Russia Smart Inhalers, by Indication, 2020-2030 ($Million)
Table 40. Russia Smart Inhalers, by End-user, 2020-2030 ($Million)
Table 41. Rest of Europe Smart Inhalers, by Product, 2020-2030 ($Million)
Table 42. Rest of Europe Smart Inhalers, by Indication, 2020-2030 ($Million)
Table 43. Rest of Europe Smart Inhalers, by End-user, 2020-2030 ($Million)
Table 44. Asia-Pacific Smart Inhalers, by Product, 2020-2030 ($Million)
Table 45. Asia-Pacific Smart Inhalers, by Indication, 2020-2030 ($Million)
Table 46. Asia-Pacific Smart Inhalers, by End-user, 2020-2030 ($Million)
Table 47. China Smart Inhalers, by Product, 2020-2030 ($Million)
Table 48. China Smart Inhalers, by Indication, 2020-2030 ($Million)
Table 49. China Smart Inhalers, by End-user, 2020-2030 ($Million)
Table 50. Japan Smart Inhalers, by Product, 2020-2030 ($Million)
Table 51. Japan Smart Inhalers, by Indication, 2020-2030 ($Million)
Table 52. Japan Smart Inhalers, by End-user, 2020-2030 ($Million)
Table 53. India Smart Inhalers, by Product, 2020-2030 ($Million)
Table 54. India Smart Inhalers, by Indication, 2020-2030 ($Million)
Table 55. India Smart Inhalers, by End-user, 2020-2030 ($Million)
Table 56. Australia Smart Inhalers, by Product, 2020-2030 ($Million)
Table 57. Australia Smart Inhalers, by Indication, 2020-2030 ($Million)
Table 58. Australia Smart Inhalers, by End-user, 2020-2030 ($Million)
Table 59. Rest of Asia-Pacific Smart Inhalers, by Product, 2020-2030 ($Million)
Table 60. Rest of Asia-Pacific Smart Inhalers, by Indication, 2020-2030 ($Million)
Table 61. Rest of Asia-Pacific Smart Inhalers, by End-user, 2020-2030 ($Million)
Table 62. Lamea Smart Inhalers, by Product, 2020-2030 ($Million)
Table 63. Lamea Smart Inhalers, by Indication, 2020-2030 ($Million)
Table 64. Lamea Smart Inhalers, by End-user, 2020-2030 ($Million)
Table 65. Brazil Smart Inhalers, by Product, 2020-2030 ($Million)
Table 66. Brazil Smart Inhalers, by Indication, 2020-2030 ($Million)
Table 67. Brazil Smart Inhalers, by End-user, 2020-2030 ($Million)
Table 68. Saudi Arabia Smart Inhalers, by Product, 2020-2030 ($Million)
Table 69. Saudi Arabia Smart Inhalers, by Indication, 2020-2030 ($Million)
Table 70. Saudi Arabia Smart Inhalers, by End-user, 2020-2030 ($Million)
Table 71. Uae Smart Inhalers, by Product, 2020-2030 ($Million)
Table 72. Uae Smart Inhalers, by Indication, 2020-2030 ($Million)
Table 73. Uae Smart Inhalers, by End-user, 2020-2030 ($Million)
Table 74. Turkey Smart Inhalers, by Product, 2020-2030 ($Million)
Table 75. Turkey Smart Inhalers, by Indication, 2020-2030 ($Million)
Table 76. Turkey Smart Inhalers, by End-user, 2020-2030 ($Million)
Table 77. Rest of LAMEA Smart Inhalers, by Product, 2020-2030 ($Million)
Table 78. Rest of LAMEA Smart Inhalers, by Indication, 2020-2030 ($Million)
Table 79. Rest of LAMEA Smart Inhalers, by End-user, 2020-2030 ($Million)
Table 80. Adherium Limited: Key Executives
Table 81. Adherium Limited: Company Snapshot
Table 82. Adherium Limited: Operating Segments
Table 83. Adherium Limited: Product Portfolio
Table 84. Adherium Limited: Key Strategic Moves and Developments
Table 85. Aptar Group Inc. (Cohero Health Inc. ): Key Executives
Table 86. Aptar Group Inc. (Cohero Health Inc. ): Company Snapshot
Table 87. Aptar Group Inc. (Cohero Health Inc. ): Operating Segments
Table 88. Aptar Group Inc. (Cohero Health Inc. ): Product Portfolio
Table 89. Aptar Group Inc. (Cohero Health Inc. ): Key Strategic Moves and Developments
Table 90. Astrazeneca, Inc. : Key Executives
Table 91. Astrazeneca, Inc. : Company Snapshot
Table 92. Astrazeneca, Inc. : Operating Segments
Table 93. Astrazeneca, Inc. : Product Portfolio
Table 94. Astrazeneca, Inc. : Key Strategic Moves and Developments
Table 95. Cognita Labs, LLC: Key Executives
Table 96. Cognita Labs, LLC: Company Snapshot
Table 97. Cognita Labs, LLC: Operating Segments
Table 98. Cognita Labs, LLC: Product Portfolio
Table 99. Cognita Labs, LLC: Key Strategic Moves and Developments
Table 100. GlaxoSmithKline plc: Key Executives
Table 101. GlaxoSmithKline plc: Company Snapshot
Table 102. GlaxoSmithKline plc: Operating Segments
Table 103. GlaxoSmithKline plc: Product Portfolio
Table 104. Novartis Ag: Key Executives
Table 105. Novartis Ag: Company Snapshot
Table 106. Novartis Ag: Operating Segments
Table 107. Novartis Ag: Product Portfolio
Table 108. Novartis Ag: Key Strategic Moves and Developments
Table 109. Opko Health Inc. : Key Executives
Table 110. Opko Health Inc. : Company Snapshot
Table 111. Opko Health Inc. : Operating Segments
Table 112. Opko Health Inc. : Product Portfolio
Table 113. Philip Morris International Inc. (Vectura Group plc): Key Executives
Table 114. Philip Morris International Inc. (Vectura Group plc): Company Snapshot
Table 115. Philip Morris International Inc. (Vectura Group plc): Operating Segments
Table 116. Philip Morris International Inc. (Vectura Group plc): Product Portfolio
Table 117. Philip Morris International Inc. (Vectura Group plc): Key Strategic Moves and Developments
Table 118. Resmed Inc. (Propeller Health): Key Executives
Table 119. Resmed Inc. (Propeller Health): Company Snapshot
Table 120. Resmed Inc. (Propeller Health): Operating Segments
Table 121. Resmed Inc. (Propeller Health): Product Portfolio
Table 122. Resmed Inc. (Propeller Health): Key Strategic Moves and Developments
Table 123. Teva Pharmaceutical Industries Ltd. : Key Executives
Table 124. Teva Pharmaceutical Industries Ltd. : Company Snapshot
Table 125. Teva Pharmaceutical Industries Ltd. : Operating Segments
Table 126. Teva Pharmaceutical Industries Ltd. : Product Portfolio
Table 127. Teva Pharmaceutical Industries Ltd. : Key Strategic Moves and Developments
List of Figures
Figure 1. Global Smart Inhalers Market Segmentation
Figure 2. Global Smart Inhalers Market
Figure 3. Segmentation Smart Inhalers Market
Figure 4. Top Investment Pocket in Smart Inhalers Market
Figure 5. Top Winning Strategies, 2019-2021*
Figure 6. Top Winning Strategies, by Development, 2019-2021(%)
Figure 7. Top Winning Strategies, by Company, 2019-2021*
Figure 8. Moderate Bargaining Power of Buyers
Figure 9. Moderate Bargaining Power of Suppliers
Figure 10. Moderate Threat of New Entrants
Figure 11. Low Threat of Substitution
Figure 12. High Competitive Rivalry
Figure 13. Top Player Positioning, 2020
Figure 14. Market Share Analysis, 2020
Figure 15. Restraints and Drivers: Smart Inhalers Market
Figure 16. Smart Inhalers Market Segmentation, by Product
Figure 17. Smart Inhalers Market for Inhalers, by Country, 2020-2030 ($ Million)
Figure 18. Smart Inhalers Market for Nebulizers, by Country, 2020-2030 ($ Million)
Figure 19. Smart Inhalers Market Segmentation, by Indication
Figure 20. Smart Inhalers Market for Asthma, by Country, 2020-2030 ($ Million)
Figure 21. Smart Inhalers Market for Copd, by Country, 2020-2030 ($ Million)
Figure 22. Smart Inhalers Market Segmentation, by End-user
Figure 23. Smart Inhalers Market for Hospital Pharmacies, by Country, 2020-2030 ($ Million)
Figure 24. Smart Inhalers Market for Retail Pharmacies, by Country, 2020-2030 ($ Million)
Figure 25. Adherium Limited: Net Sales, 2018-2020 ($ Million)
Figure 26. Adherium Limited: Revenue Share, by Segment, 2020 (%)
Figure 27. Adherium Limited: Revenue Share, by Region, 2020 (%)
Figure 28. Aptar Group Inc. (Cohero Health Inc. ): Net Sales, 2018-2020 ($ Million)
Figure 29. Aptar Group Inc. (Cohero Health Inc. ): Revenue Share, by Segment, 2020 (%)
Figure 30. Aptar Group Inc. (Cohero Health Inc. ): Revenue Share, by Region, 2020 (%)
Figure 31. Astrazeneca, Inc: Net Sales, 2018-2020 ($ Million)
Figure 32. Astrazeneca, Inc: Revenue Share, by Segment, 2020 (%)
Figure 33. Astrazeneca, Inc: Revenue Share, by Region, 2020 (%)
Figure 34. GlaxoSmithKline plc: Net Sales, 2018-2020 ($ Million)
Figure 35. GlaxoSmithKline plc: Revenue Share, by Segment, 2020 (%)
Figure 36. GlaxoSmithKline plc: Revenue Share, by Region, 2020 (%)
Figure 37. Novartis Ag: Net Sales, 2018-2020 ($ Million)
Figure 38. Novartis Ag: Revenue Share, by Segment, 2020 (%)
Figure 39. Novartis Ag: Revenue Share, by Region, 2020 (%)
Figure 40. Opko Health Inc: Net Sales, 2018-2020 ($ Million)
Figure 41. Opko Health Inc: Revenue Share, by Segment, 2020 (%)
Figure 42. Opko Health Inc: Revenue Share, by Region, 2020 (%)
Figure 43. Philip Morris International Inc. (Vectura Group plc): Net Sales, 2018-2020 ($ Million)
Figure 44. Philip Morris International Inc. (Vectura Group plc): Revenue Share, by Segment, 2020 (%)
Figure 45. Philip Morris International Inc. (Vectura Group plc): Revenue Share, by Region, 2020 (%)
Figure 46. Resmed Inc. (Propeller Health): Net Sales, 2018-2020 ($ Million)
Figure 47. Resmed Inc. (Propeller Health): Revenue Share, by Segment, 2020 (%)
Figure 48. Resmed Inc. (Propeller Health): Revenue Share, by Region, 2020 (%)
Figure 49. Teva Pharmaceutical Industries Ltd: Net Sales, 2018-2020 ($ Million)
Figure 50. Teva Pharmaceutical Industries Ltd: Revenue Share, by Segment, 2020 (%)
Figure 51. Teva Pharmaceutical Industries Ltd: Revenue Share, by Region, 2020 (%)

Executive Summary

According to a new report titled, Smart Inhalers Market by Product, Indication, and Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2021–2030, the global smart inhalers market was valued at $118 million in 2020, and is projected to reach $1,113.57 million by 2030, registering a CAGR of 25.1% from 2021 to 2030.

Smart inhalers are devices used for delivering several inhaled medications, such as anticholinergics, glucocorticoids, and beta antagonists for treating respiratory diseases. Smart inhalers contain sensors that are connected to inhaler devices, which allows maintaining the record of inhaler, increasing the adherence, and monitoring of the patient.

A smart inhaler is an inhaler that is improved by technology. These medical devices make use of technology to aid in the collection of health data. This information can assist the doctor to note more personalised treatment decisions. Some smart inhalers have sensors that can detect if a person is in a high-pollution or high-pollen area, while others can send helpful reminders and tell if one needs to check the inhaler technique. They're all designed to automatically track how frequently one uses its inhaler, so one does not have to keep track of it.

The growth of the smart inhalers market is majorly driven due to rise in prevalence of asthma and COPD. Moreover, increase in air pollution and rise in indoor air pollutant further increase the chances of having respiratory disorders. Better treatment option, ease of use, and technological advancements coupled with increase in adherence rate of patients to smart inhalers are major factors that drive the smart inhalers market.

Furthermore, according to the U.S. Centers for Disease Control and Prevention, in 2019, around 25.1 million people were suffering from asthma, including 5.1 million children. Thus, such high number of patients is expected to boost the market significantly.

Moreover, in September 2021, Adherium Limited announced that it had received U.S. Food and Drug Administration (FDA) 510(k) clearance to market its first, next generation Hailie sensor with physiological measures for monitoring asthma and (COPD) medication use. It is designed for use with AstraZeneca’s Symbicort aerosol inhaler, to enable physicians and providers to enhance patient care and clinical workflow by capturing clinical data and supporting patient management and treatment. Thus, such collaborations and product approval strategies among the key players are expected to propel the market growth significantly.

However, risk of misuse of data and and breach of data privacy, high cost of asthma & COPD treatment, and low awareness about smart inhalers are expected to impede the market growth. Conversely, high market potential in the untapped emerging economies, rise in various product launches, partnerships, collaborations among the government & key players, and development of pipeline products are expected to provide many opportunities for market growth during the forecast period.

By product type, the market is segmented into inhalers and nebulizers. The inhalers segment generated maximum revenue in 2020, accounting $112.86 million. The nebulizers segment is expected to witness highest CAGR of 27.3% during the forecast period.

By indication, the market is segmented into asthma and COPD. The asthma segment generated maximum revenue in 2020, accounting $63.55 million. The COPD segment is expected to witness highest CAGR of 25.4% during the forecast period.

On the basis of distribution channel, the market is segmented into hospital pharmacies and retail pharmacies. The retail pharmacies segment generated maximum revenue in 2020, accounting $69.21 million and is expected to witness highest CAGR of 25.4% during the forecast period.

North America exhibited the global smart inhalers market share in 2020, and is anticipated to remain dominant during the forecast period. This is attributed to better healthcare infrastructure and facilities, prevalence in the number of patient suffering from asthma and COPD, adoption of technologically advanced treatments, presence of key players, and rise healthcare expenditure in the region. However, Asia-Pacific is anticipated to witness notable growth, owing to its high geriatric population base, increase in disposable incomes, surge in healthcare expenditure, and various developmental activities.

Key Findings Of The Study


  • By product, inhaler segment was the highest contributor to the market in 2020
  • By indication, asthma segment was the highest contributor to the market in 2020
  • On the basis of distribution channel, retail pharmacies segment was the highest contributor to the market in 2020
  • Region wise, North America garnered the largest revenue share in 2020, whereas Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period

Companies Mentioned

  • Adherium Limited
  • Aptar Group Inc. (Cohero Health Inc.)
  • AstraZeneca, Inc.
  • Cognita Labs, Llc.
  • GlaxoSmithKline Plc
  • Novartis AG
  • OPKO Health Inc.
  • Philip Morris International Inc. (Vectura Group Plc)
  • ResMed Inc. (Propeller Health)
  • Teva Pharmaceutical Industries Ltd.

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...

Table Information